中危前列腺癌放疗联合或不联合雄激素剥夺治疗
结果显示,≤70岁 favorable 中危患者单纯放疗者生化失败风险增加(HR 3.06,P=0.025),生化无复发生存率82.1% vs 94.0%(P=0.030);>70岁患者联合治疗无差异(P=0.87)。
要点
- ≤70岁 favorable 中危患者单纯放疗至78 Gy生化失败风险增加。
- 该组患者联合ADT者生化无复发生存率显著更高。
- >70岁患者联合ADT与否生化失败无差异。
核心结论
- ≤70岁 favorable 中危前列腺癌患者单纯放疗至78 Gy生化失败风险增加,应考虑短期ADT。
- >70岁患者联合ADT未显示生化失败获益。
研究设计与样本
- 所有患者接受适形放疗至前列腺,绝大多数未接受淋巴结照射;ADT于放疗前2个月开始并持续至放疗后4个月。
主要发现
- 联合ADT组较单纯放疗组有更多阳性穿刺针数、更高放疗前PSA、更多中危因素及更常接受盆腔淋巴结放疗。
- favorable 单纯放疗组与 unfavorable 联合ADT组在生化、局部或远处失败及生存方面无差异。
- 多因素分析显示≤70岁单纯放疗患者6年随访期间生化失败风险增加(HR 3.06,P=0.025)。
- ≤70岁单纯放疗者生化无复发生存率为82.1%,联合ADT者为94.0%(P=0.030)。
- >70岁患者联合治疗与否生化失败无差异(P=0.87)。
关键数值与推荐
- favorable 中危患者单纯放疗至78 Gy。
- ≤70岁单纯放疗者生化无复发生存率82.1%,联合ADT者94.0%(P=0.030)。
- ≤70岁单纯放疗生化失败HR 3.06(P=0.025)。
- >70岁联合治疗比较P=0.87。
临床怎么用
- ≤70岁 favorable 中危前列腺癌患者接受单纯放疗至78 Gy时,可考虑联合短期ADT以降低生化失败风险。
- >70岁患者联合ADT的必要性需个体化评估。
局限性
- 回顾性研究,存在选择偏倚。
- 单中心经验,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Androgen deprivation therapy (ADT) is beneficial for unfavorable intermediate-risk (IR) prostate cancer patients receiving curative radiotherapy (RT). However, for favorable IR patients the latest NCCN guidelines recommends RT alone. We retrospectively studied treatment patterns and outcomes of patients with IR prostate cancer in our institution over the past two decades. MATERIALS AND METHODS: Three hundred seventy-three IR prostate cancer patients treated with definitive RT between 5/2002-5/2016 were identified in an institutional review board approved database. All patients received conformal RT to the prostate while the vast majority did not receive nodal radiation. ADT was commenced 2 months prior to RT and was continued for 4 months after RT. RESULTS: Compared to RT alone, patients receiving combined RT+ ADT had more positive biopsy cores, higher pre-radiation PSA, more IR factors, and were more likely to receive pelvic lymph node radiation. However, there were no differences in failure either biochemical, local or distal, nor on survival between the favorable RT alone and the unfavorable RT+ ADT cohorts, suggesting a beneficial role for ADT. On multivariate analysis, patients 70 years or younger receiving RT alone were at increased risk for biochemical failure during a 6-year follow-up (HR 3.06, P = 0.025). Biochemical relapse free survival in patients ≤70 years who received RT alone was 82.1% vs 94.0% for RT + ADT (P = 0.030). There was no difference for combined treatment modality in patients > 70 years (P = 0.87). CONCLUSIONS: Men 70 years or younger with favorable IR prostate cancer treated with RT alone to 78 Gy are at increased risk of biochemical failure. Short term ADT should be considered in this cohort of men.
引用
- Amit U, Lawrence YR, Weiss I, et al. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer? Radiat Oncol. 2019. PMID: 31182119. doi:10.1186/s13014-019-1298-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。